State Street
CARM

State Street’s Carisma Therapeutics CARM Stock Holding History

State Street’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-85,106
Closed -$23.3K – 4299
2025
Q3 		$23.3K Hold
85,106
– – ﹤0.01% 4234
2025
Q2 		$33.3K Hold
85,106
– – ﹤0.01% 4152
2025
Q1 		$26.4K Hold
85,106
– – ﹤0.01% 4176
2024
Q4 		$35.6K Hold
85,106
– – ﹤0.01% 4161
2024
Q3 		$83.5K Hold
85,106
– – ﹤0.01% 4012
2024
Q2 		$129K Sell
85,106
-439,999
-84% -$656K ﹤0.01% 3934
2024
Q1 		$1.19M Buy
525,105
+24,794
+5% +$59.6K ﹤0.01% 3424
2023
Q4 		$1.47M Buy
500,311
+18,192
+4% +$54.1K ﹤0.01% 3396
2023
Q3 		$2.04M Buy
482,119
+6,955
+1% +$44K ﹤0.01% 3324
2023
Q2 		$4.17M Buy
475,164
+441,821
+1,325% +$2.41M ﹤0.01% 3081
2023
Q1 		$103K Sell
33,343
-5
-0% -$48 ﹤0.01% 4315
2022
Q4 		$407K Hold
33,348
– – ﹤0.01% 3841
2022
Q3 		$283K Hold
33,348
– – ﹤0.01% 3988
2022
Q2 		$541K Sell
33,348
-183,604
-85% -$2.1M ﹤0.01% 3800
2022
Q1 		$2.62M Buy
216,952
+2,614
+1% +$36.5K ﹤0.01% 3470
2021
Q4 		$3.49M Buy
214,338
+13,735
+7% +$276K ﹤0.01% 3409
2021
Q3 		$3.18M Sell
200,603
-483,187
-71% -$23.2M ﹤0.01% 3463
2021
Q2 		$63.2M Buy
683,790
+677,925
+11,559% +$43.2M ﹤0.01% 1675
2021
Q1 		$305K Buy
5,865
+340
+6% +$16K ﹤0.01% 3788
2020
Q4 		$149K Buy
+5,525
New +$140K ﹤0.01% 3781
2020
Q1 		– Sell
-640
Closed -$13K – 3764
2019
Q4 		$13K Buy
+640
New +$14.7K ﹤0.01% 3778
2019
Q2 		– Sell
-7,337
Closed -$151K – 3823
2019
Q1 		$151K Buy
7,337
+179
+3% +$3.09K ﹤0.01% 3601
2018
Q4 		$203K Buy
+7,158
New +$228K ﹤0.01% 3578
2018
Q3 		– Sell
-575
Closed -$22K – 3775
2018
Q2 		$22K Buy
+575
New +$25.3K ﹤0.01% 3726
2015
Q2 		– Sell
-3,422
Closed -$612K – 3727
2015
Q1 		$612K Buy
3,422
+12
+0.4% +$2.62K ﹤0.01% 3333
2014
Q4 		$810K Buy
3,410
+373
+12% +$83.7K ﹤0.01% 3305
2014
Q3 		$676K Buy
3,037
+86
+3% +$20.4K ﹤0.01% 3334
2014
Q2 		$778K Buy
2,951
+1,507
+104% +$373K ﹤0.01% 3281
2014
Q1 		$469K Buy
+1,444
New +$432K ﹤0.01% 3371

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

State Street's CARM Position: Q4 2025 in Review

State Street sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 85,106 shares — an estimated $23.3K sold.

State Street first reported a position in CARM in Q1 2014 and held it in 29 quarters. The position peaked at $63.2M in Q2 2021. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • State Street reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • State Street sold 85,106 Carisma Therapeutics shares in Q4 2025, an estimated $23.3K.
  • State Street first reported a position in Carisma Therapeutics in Q1 2014 and held it in 29 quarters.
  • State Street's Carisma Therapeutics position peaked at $63.2M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on State Street's 13F filing for Q4 2025, filed 13 Feb 2026.